Skip to content

Ovid Therapeutics Inc.

OVID

CIK 0001636651

← back to feed
Revenue (TTM)
$6.53M
+1,181.3% YoY Q1 May 2026
Net Income (TTM)
−$44.07M
+34.1% YoY Q1 May 2026
EPS Diluted (TTM)
−$0.41
+3.9% YoY Q1 May 2026
Gross Margin
—
Q1 May 2026
Operating Margin
-734.5%
Q1 May 2026
Net Margin
-674.4%
Q1 May 2026
Free Cash Flow (TTM)
−$53.06M
Q1 May 2026
Cash
$94.06M
Q1 May 2026
Total Debt
—
Q1 May 2026
Shares Outstanding
186.64M sh
Q1 May 2026

Revenue & Net Income

EPS (Diluted)

Margins

Cash Flow

Revenue Growth (YoY)

Balance Sheet

Cash vs Debt

Recent filings